| Novartis Pharma Schweiz AG - Jakavi 15 mg, Tabletten |
| 62126 | | 02 | | Jakavi 15 mg | | Tabletten | | L01EJ01 | | Ruxolitinib | | 27.12.2012 | | |
|
| Composition |
| ruxolitinibum 15 mg ut ruxolitinibi phosphas, lactosum monohydricum 214.35 mg, cellulosum microcristallinum, carboxymethylamylum natricum A, hydroxypropylcellulosum, povidonum K 30, silica colloidalis anhydrica, magnesii stearas, pro compresso corresp. natrium 0.97 mg. |
| Packungsbestandteile |
| Tablets | | | | | Active Agent | Dose |
|---|
| Ruxolitinibum | 15 mg |
| | BAG: Active Agent | Dose |
|---|
| Ruxolitinibum | 15 mg |
| | | | Inactive agents | Dose |
|---|
| Carboxymethylamylum Natricum A | | | Cellulosum Microcristallinum | | | Hydroxypropylcellulosum | | | Lactose Monohydrate | 214.35 mg | | Magnesii Stearas | | | Povidonum K | 30 | | Pro Compresso | | | Silica Colloidalis Anhydrica | |
| |
|
| Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 004 | 56 Tablet(s) | 3143.42 | 3435.05 | A | SL | Yes | | 005 | 3 x 56 Tablet(s) | PR | PR | A | | Yes |
|
